Table 63.
Matrix | Presumptive ESBL and/or AmpC producersa n (%R) | Presumptive ESBL producersb n (%R) | Presumptive AmpC producersc n (%R) | Presumptive ESBL+AmpC producers n (%R) | Presumptive CP producers n (%R) |
---|---|---|---|---|---|
Humans (N = 8,746, 13 MSs) | 76 (0.9) | 70 (0.8) | 5 (0.1) | 0 (< 0.01) | 0 (< 0.01) |
Meat from broilers (N = 763, 19 MSs) | 19 (2.5) | 16 (2.1) | 5 (0.7) | 2 (0.6) | 0 (< 0.48) |
Broilers (N = 1,717, 22 MSs) | 14 (0.8) | 11 (0.6) | 3 (0.2) | 0 (< 0.21) | 0 (< 0.21) |
Meat from turkeys (N = 295, 8 MSs) | 3 (1.0) | 3 (1.0) | 1 (0.3) | 1 (0.3) | 0 (< 1.3) |
Fattening turkeys (N = 663, 11 MSs) | 6 (0.9) | 6 (0.9) | 0 (< 0.6) | 0 (< 0.6) | 0 (< 0.6) |
Laying hens (N = 1,216, 22 MSs) | 1 (0.1) | 1 (0.1) | 0 (< 0.3) | 0 (< 0.3) | 0 (< 0.3) |
N: Total number of isolates reported for this monitoring by the MSs; n: number of the isolates resistant; % R: percentage of resistant isolates; ESBL: extended‐ spectrum β‐lactamase. MS: EU Member States.
Isolates exhibiting only ESBL‐ and/or only AmpC‐ and/or ESBL+AmpC phenotype.
Isolates exhibiting an ESBL‐ and ESBL+AmpC phenotype.
Isolates exhibiting an AmpC‐ and ESBL+AmpC phenotype.